Testing for egfr mutations and alk rearrangements in advanced non-small-cell lung cancer: Considerations for countries in emerging markets
Por:
Dalurzo M.L., Avilés-Salas A., Soares F.A., Hou Y., Li Y., Stroganova A., Öz B., Abdillah A., Wan H., Choi Y.-L.
Publicada:
1 ene 2021
Resumen:
The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years has been increasingly guided by biomarker testing. Testing has centered on driver genetic alterations involving the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements. The presence of these mutations is predictive of response to targeted therapies such as EGFR tyrosine kinase inhibitors (TKIs) and ALK TKIs. However, there are substantial challenges for the implementation of bio-marker testing, particularly in emerging countries. Understanding the barriers to testing in NSCLC will be key to improving molecular testing rates worldwide and patient outcomes as a result. In this article, we review EGFR mutations and ALK rearrangements as predictive biomarkers for NSCLC, discuss a selection of appropriate tests and review the literature with respect to the global uptake of EGFR and ALK testing. To help improve testing rates and unify procedures, we review our experiences with biomarker testing in China, South Korea, Russia, Turkey, Brazil, Argentina and Mexico, and propose a set of recommendations that pathologists from emerging countries can apply to assist with the diagnosis of NSCLC. © 2021 Dalurzo et al.
Filiaciones:
Dalurzo M.L.:
Department of Pathology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Avilés-Salas A.:
Department of Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico
Soares F.A.:
Department of Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil
Hou Y.:
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China
Li Y.:
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Stroganova A.:
N.N. Blokhin National Medical Research Centre of Oncology, Russian Academy of Medical Sciences, Moscow, Russian Federation
Öz B.:
Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
Abdillah A.:
Takeda Pharmaceuticals International AG – Singapore Branch, Singapore, Singapore
Wan H.:
Takeda Pharmaceuticals International AG – Singapore Branch, Singapore, Singapore
Choi Y.-L.:
Department of Pathology and Translational Genomics, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea
Gold
|